Rituximab for Multiple Sclerosis-Reference-Cited by-同舟云学术

Rituximab for Multiple Sclerosis

Published:2024-01-23 Issue:2 Volume:102 Page:
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Langer-Gould Annette¹,Sotirchos Elias S.¹,Bourdette Dennis¹

Affiliation:

1. From the Department of Neurology (A.L.-G.), Los Angeles Medical Center, Southern California Permanente Medical Group; Department of Clinical Science (A.L.-G.), Kaiser Permanente School of Medicine, Pasadena, CA; Department of Neurology (E.S.S.), Johns Hopkins University School of Medicine, Baltimore, MD; and Department of Neurology (D.B.), Oregon Health & Science University, Portland.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Link

https://www.neurology.org/doi/pdfdirect/10.1212/WNL.0000000000208063

Reference5 articles.

1. Institute for Clinical and Economic Review (ICER). Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: final policy recommendations; 2023. Accessed July 27 2023. icer.org/wp-content/uploads/2023/02/ICER_MS_Policy_Recommendations.pdf.

2. World Health Organization. The selection and use of essential medicines 2023: Executive summary of the report of the 24th WHO expert committee on the selection and use of essential medicines. Accessed August 11 2023. apps.who.int/iris/bitstream/handle/10665/371291/WHO-MHP-HPS-EML-2023.01-eng.pdf.

3. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis

4. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

5. Decreasing Multiple Sclerosis Treatment Expenditures and Improving Quality at the Health System Level